Jane Gross
Direktor/Vorstandsmitglied bei ATYR PHARMA, INC.
Vermögen: 9 570 $ am 30.04.2024
Profil
Dr. Jane A.
Gross is an Independent Director at BriaCell Therapeutics Corp., an Independent Director at aTyr Pharma, Inc. and an Independent Director at BriaPro Therapeutics Corp.
She is on the Board of Directors at BriaCell Therapeutics Corp., aTyr Pharma, Inc., Washington Biotechnology & Biomedical Association and BriaPro Therapeutics Corp.
Dr. Gross was previously employed as a Chief Scientific Officer & Senior Vice President by Aptevo Therapeutics, Inc., a VP-Applied Research & Non-Clinical Development by Emergent BioSolutions, Inc., and a Vice President-Immunology Research by ZymoGenetics, Inc. She received her doctorate degree from the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ATYR PHARMA, INC.
0,01% | 01.03.2024 | 6 000 ( 0,01% ) | 9 570 $ | 30.04.2024 |
| 20.12.2023 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Jane Gross
| Unternehmen | Position | Beginn |
|---|---|---|
| ATYR PHARMA, INC. | Direktor/Vorstandsmitglied | 28.06.2019 |
| BRIACELL THERAPEUTICS CORP. | Direktor/Vorstandsmitglied | 01.11.2021 |
| Washington Biotechnology & Biomedical Association | Direktor/Vorstandsmitglied | - |
BriaPro Therapeutics Corp.
 BriaPro Therapeutics Corp. Pharmaceuticals: MajorHealth Technology BriaPro Therapeutics Corp. a clinical stage biotechnology company focuses on the development of BriaTILsRx™ and PKCd inhibitors for multiple indications including cancer. The company was founded on May 15, 2023 and is headquartered West Vancouver, Canada. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jane Gross
| Unternehmen | Position | Ende |
|---|---|---|
| APTEVO THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 14.09.2021 |
| EMERGENT BIOSOLUTIONS INC. | Corporate Officer/Principal | 01.08.2016 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | 01.06.2010 |
Ausbildung von Jane Gross
| University of California, Berkeley | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| APTEVO THERAPEUTICS INC. | Health Technology |
| BRIACELL THERAPEUTICS CORP. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
| Washington Biotechnology & Biomedical Association | |
BriaPro Therapeutics Corp.
BriaPro Therapeutics Corp. Pharmaceuticals: MajorHealth Technology BriaPro Therapeutics Corp. a clinical stage biotechnology company focuses on the development of BriaTILsRx™ and PKCd inhibitors for multiple indications including cancer. The company was founded on May 15, 2023 and is headquartered West Vancouver, Canada. | Health Technology |
